Study the correlation of iodine nutrition and autoimmunity among Euthyroid goiter patient in a tertiary care hospital in Tamil Nadu

Suresh Pichandi¹, Sivakumar J², Janakiraman P³, Ramadevi K⁴

¹Associate Professor, Department of Biochemistry, Sri Venkateshwaraa Medical College and Research Centre, Puducherry, ²Associate Professor, Department of Biochemistry, Dhanalakshmi Srinivasan Medical College and Hospital, Perambalur, Tamil Nadu, ³Tutor in Statistics, Department of Community Medicine, PES Institute of Medical Sciences and Research, Kuppam, Andra Pradesh, ⁴Professor and Head, Institute of Biochemistry, Madras Medical College and Government Rajiv Gandhi General Hospital, Chennai, Tamil Nadu, India

ABSTRACT

Background: Iodine is an essential micronutrient for the thyroid hormone synthesis. It is crucial for the growth and development of human life. Deficient or excessive iodine intake may affect thyroid gland size and functions. Despite the intake of iodized salt, the increasing occurrence of thyroid disorders in India. Aims and Objectives: The aim of the present study is to analyze the nutritional status of iodine among Euthyroid goiter patients by measuring urinary excretion and correlate with thyroid hormone and autoantibodies. Materials and Methods: One hundred and fifty Euthyroid goiter patients and one hundred and fifty age-matched normal adult were included in this study. Urinary Iodine level and serum TSH, freeT4, freeT3, AMA, and ATG were estimated both case and control groups. Results: The mean urinary iodine excretion concentration in Euthyroid goiter patient was 244.39µg/L and excess urinary iodine excretion was found in 48%. There were elevated serum AMA levels in Euthyroid goiter patient and that positive correlated with excess iodine. Conclusion: In this study, we found that excess urinary iodine excretion among patients. This study we observed iodine excess associated complications, viz., benign goiter (49%), thyroiditis (24%), cancer of thyroid (21%), and thyrotoxicosis (8%).

Key words: Goiter; Iodine excess; Thyroiditis; Urinary iodine excretion; World Health Organization

INTRODUCTION

Iodine is an essential micronutrient for the thyroid hormone synthesis. It is crucial for the growth and development of human life.¹ Iodine is mostly concentrated in the thyroid gland and about 70–80% is stored in the thyroid gland.² Daily physiological requirement of Iodine in adult life is 150 micrograms³ and recommended daily intake for different age groups is given by the World Health Organization (WHO) (Table 1).⁴ Thyroid gland plays an important role in the metabolism of iodine. Deficient or excessive iodine intake may affect thyroid gland size and functions.⁵ Iodine deficiency affects two billion people worldwide approximately.⁶ Iodine deficiency disorders (IDD), including stunted physical growth, squint, abortion, stillbirths, deafness, neonatal cretinism, impaired mental abilities, hypothyroidism, and its complications.⁷ Eradicate the IDD, Universal salt iodination program was implemented.⁸ Since iodine is released from the body through urine, the WHO recommended Urinary iodine measurement is a good marker of dietary iodine intake.⁹ USI program has eliminated iodine deficiency from goiter endemic areas but goiter prevalence has not been eliminated. The past decade study reports say that the occurrence of thyroid-related disorders with iodine excess...
Excess intake has been found to be associated with iodine-induced hyperthyroidism, iodine-induced hypothyroidism, and iodine-induced goiter. It prompted us to investigate the iodine status among Euthyroid goiter patients and to correlate with the thyroid function.

### Aims and objectives

The aim of the present study is to analyze the nutritional status of iodine among Euthyroid goiter patient by measuring urinary excretion and correlate with thyroid hormone and autoantibodies.

### MATERIALS AND METHODS

In this study, the samples were collected from the patients of the Department of Endocrine Surgery, Madras Medical College and Rajiv Gandhi Government General Hospital Chennai. This study was pre-approved by the Institutional Ethics Committee. 150 Euthyroid goiter patients and 150 age-matched normal adults were included in the study. Urinary Iodine estimation and serum Thyroid Stimulating Hormone, free thyroxin fT4, free triiodothyronine, anti-microsomal antibody (AMA), and anti-thyroglobulin antibody, were estimated for case and control groups. Grading of goiter was determined according to the criteria recommended by the WHO/UNICEF/ICCIDD.

Grading of goiter was determined according to the criteria recommended by the WHO/UNICEF/ICCIDD. The following types of goiter based on palpation were identified among the Euthyroid patients: GradeI-7 %, GradeII-68%, GradeIII -25%.

Based on the results obtained, the patients were classified into 2 types:

**Type I: Urinary iodine excretion**

Based on the urinary iodine level, the Euthyroid goiter patients were classified into four groups (Figure 2). Using the WHO criteria, iodine nutrition, as assessed by the mean urinary iodine excretion of Euthyroid goiter patients, is described in (Figure 2). Only 15% of the Euthyroid patients had iodine deficiency, while 54% had more than adequate iodine nutrition and among that 34 % had very high excretion of iodine (>300 µg/L) and normal iodine status was 31%.

**Type II: Pathophysiological classification**

Based on the thyroid hormone profile, and antibody titters, the 150 Euthyroid goiter patients were classified into four groups (Figure 3). The comparison was done among Benign, thyroiditis, cancer of thyroid and thyrotoxicosis goiter patient’s

Table 1: WHO recommendations for daily dietary intake of iodine

| Age or population group | Iodine intake in micrograms per day (µg/day) |
|-------------------------|---------------------------------------------|
| Children 0–5 years      | 90                                          |
| Children 6–12 years     | 120                                         |
| Adults>12 years         | 150                                         |
| Pregnancy               | 250                                         |
| Lactation               | 250                                         |

WHO: World Health Organization

**Figure 1:** Patient statistics of department of endocrine surgery of a tertiary care hospital in South India (11)
Pichandi, et al.: Study the correlation of iodine nutrition and autoimmunity among Euthyroid goiter patient in a tertiary care hospital in Tamil Nadu

Table 2: Case control thyroid profile for adult group

| Variable         | Case (n=150)       | Control (n=150) | P-value |
|------------------|--------------------|-----------------|---------|
| Age (Years)      | 41.08±9.31         | 35.11±9.49      | <0.001**|
| UIE (µg/L)       | 244.39±140.80      | 153.45±35.86    | <0.001**|
| Ref. Range (100–200) | 2.02±1.12         | 1.86±0.87       | 0.1936  |
| TSH (micro IU/ml)| 1.63±0.98          | 1.62±0.29       | 0.3192  |
| Ref. Range (0.8–2.0) | 2.63±0.57         | 2.69±0.66       | 0.3406  |
| FT4 (ng/dl)      |                   |                 |         |
| Ref. Range (2.0–4.4) | 22                | 47              |         |
| FT3 (pg/dl)      |                   |                 |         |
| Ref. Range (2.0–4.4) | 30                | 30              |         |
| P-value          |                   |                 |         |

*P<0.05 Statistically significant, **P<0.01 Statistically significant. UIE: Urinary iodine excretion, TSH: Thyroid stimulating hormone, FT4: Free thyroxin, FT3: Free triiodothyronine

DISCUSSION

Iodine excess is the hallmark that is observed among our patients in this study. These results showed that there is no iodine deficiency among the patients and the USI program has also eliminated the iodine deficiency as reported by many studies. The mean urinary iodine excretion patients group was 244.39±140.80 µg/L while the controls had 153.45±35.86 (Table 2), P<0.001. Only 15% of the Euthyroid patients had iodine deficiency, while 54% had more than adequate iodine nutrition and among that very high excretion of iodine (>300 µg/L) was 34%, while normal iodine excretion status was 31%.

Our study result shows that there were excess urinary iodine excretions in Euthyroid goiter patients. We have been observed excess iodine complications, viz., benign goiter (49%), thyroiditis (24%), thyrotoxicosis (6%) and cancer of the thyroid (21%) in this study.

The mechanism behind the pathophysiology of endemic goiter caused by excessive iodine intake may involve the damage to thyroid parenchyma. Autoimmune growth factors such as thyroid growth-stimulating immunoglobulin may play a primary role in the pathogenesis of thyroid growth in this condition. Iodine supplementation was found to be accompanied by a change in the epidemiological pattern of thyroid cancer with an increased prevalence of papillary cancer discovered at autopsy.
Table 3: Physiological classification of Euthyroid disorder

| Variable | THYROIDITIS | TOXIC | BENIGN | PAP CA |
|----------|-------------|-------|--------|--------|
|          | Median±IQR  | Median±IQR | Median±IQR | Median±IQR |
| UI       | 205 (300–150) | 320 (380–85) | 242 (350–135) | 207.5 (350–126) |
| TSH      | 1.9 (3.3–1.3) | 1.3 (2.2–0.8) | 1.5 (2.5–0.9) | 1.9 (2.9–1.2) |
| FT3      | 2.8 (3.1–2.5) | 3.3 (3.1–2.5) | 2.8 (2.9–2.4) | 2.7 (2.9–2.4) |
| FT4      | 1.3 (1.9–0.9) | 1.3 (2.5–1.3) | 1.3 (2.2–1.1) | 1.2 (1.6–1.0) |
| AMA      | 91.4 (97.6–79.1) | 97.6 (100–88.6) | 97.6 (97.6–85.2) | 94.3 (97.6–81.1) |
| ATG      | 776 (1009–238) | 456 (879–164) | 879 (1048–181) | 776 (1045–456) |

IQR: Inter quarter range, TSH: Thyroid stimulating hormone, FT4: Free thyroxin, FT3: Free triiodothyronine, AMA: Anti‑microsomal antibody, ATG: Anti‑thyroglobulin antibody.

Limitations of the study
This study has some limitations and it is a hospital-based study and sample size is small. Large sample required community-based assessment.

CONCLUSION
Iodine is adequately available in the coastal regions of our country and Tamil Nadu with a large coastal area, the chances of iodine deficiency are much less. Universal salt iodination program has also eliminated the iodine deficiency as reported by many studies. In this study we observed excess iodine excretion is the hallmark among our study patients. Excess iodine associated complications, viz., benign goiter (49%), thyroiditis (24%), cancer of thyroid (21%) and thyrotoxicosis (6%) have been observed in this study.

Chronic exposure of excess iodine, may create a generation of thyroid cripples, should be prevented by regular follow-up of iodine supplementation with careful monitoring. This small hospital-based study for urinary iodine concentration in Euthyroid goiter patient may not be representative of community iodine nutrition and similar large number of sample required for community settings to find the iodine nutrition in Euthyroid goiter patient.

ACKNOWLEDGMENT
The authors thanks members of our Endocrine Surgery unit, faculty and staff who have helped us for this work.

REFERENCES
1. WHO. Assessment of Iodine Deficiency Disorders and Monitoring their Elimination. A Guide for Programme Managers. Geneva: World Health Organization, International Council for Control of Iodine Deficiency Disorders. United Nations Children’s Fund; 2007. Available from: https://apps.who.int/iris/bitstream/ handle/10665/43781/9789241595827_eng.pdf
2. Detels R, Holland WW, McEwen HJ and Omenn GS. Oxford
Pichandi, et al.: Study the correlation of iodine nutrition and autoimmunity among Euthyroid goiter patient in a tertiary care hospital in Tamil Nadu

Textbook of Public Health. Oxford, United Kingdom: Oxford University Press; 1977. p. 1114-1115.

3. Khurana I. Textbook of Medical Physiology. India: Reed Elsevier; 2006. p. 710-715.

4. World Health Organization, ICCIDD and UNICEF. Recommended Iodine Levels in Salt and Guidelines for Monitoring their Adequacy and Effectiveness. Based on a Joint WHO/UNICEF/ICCIDD Consultation. Geneva: World Health Organization; 1996. p. 8-9.

5. Glinier D. The regulation of thyroid function in pregnancy: Pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997;18(3):404-433. https://doi.org/10.1210/edrv.18.3.0300

6. Zimmermann MB. Assessing iodine status and monitoring progress of iodized salt programs. J Nutr. 2004;134(7):1673-1677. https://doi.org/10.1093/jn/134.7.1673

7. Hetzel BS. Iodine deficiency disorders (IDD) and their eradication. Lancet. 1983;12(8359):1128-1129. https://doi.org/10.1016/s0140-6736(83)90636-0

8. Pardede LV, Hardjowasito W, Gross R, Dillon DH, Totoprajogo OS, Yosoprawoto M, et al. Urinary iodine excretion is the most appropriate outcome indicator for iodine deficiency at field conditions at district level. J Nutr. 1998;128(7):1122-1126. https://doi.org/10.1093/jn/128.7.1122

9. World Health Organization, ICCIDD and UNICEF. Assessment of Iodine Deficiency Disorders and Monitoring their Elimination: A Guide for Programme Managers. Geneva: ICCIDD, UNICEF, WHO; 2001.

10. Marwaha RK, Tandon N, Gupta N, Karak AK, Verma K and Kochupillai N. Residual goitre in the postiodization phase: Iodine status, thiocyanate exposure and autoimmunity. ClinEndocrinol (Oxf). 2003;59(6):672-681. https://doi.org/10.1046/j.1365-2265.2003.01895.x

11. Chandrasekarar M and Ramadevi K. Thyromegaly and iodine nutritional status in a tertiary care hospital in South India. Indian J EndocrinolMetab. 2013;17(2):260-264. https://doi.org/10.4103/2230-8210.109701

12. Dunn JT, Crutchfield HE, Gutekunst R and Dunn AD. Two simple methods for measuring iodine in urine. Thyroid. 1993;3(2):119-123. https://doi.org/10.1089/thy.1993.3.119

13. WHO, UNICEF and ICCIDD Consultation. Indicators for Assessing Iodine Deficiency Disorders and Their Control Programmes. Geneva: WHO; 1992.

14. Wolff J. Iodide goitre and the pharmacologic effects of excess iodide. Am J Med. 1969;47(1):101-124. https://doi.org/10.1016/0002-9343(69)90245-9

15. Boyages SC, Bloot AM, Maberly GF, Eastman CJ, Mu L, Qidong Q, et al. Thyroid autoimmunity in endemic goitre caused by excessive iodine intake. ClinEndocrinol (Oxf), 1989;31(4):453-456. https://doi.org/10.1111/j.1365-2265.1989.tb01269.x

16. Vigneri R, Pezzino V, Squatrito S, Salamone S, Giuffrida D, Rosa GL, et al. Iodine deficiency and thyroid cancer. In: Delange F, Robertson A and McLoughney E, editors. Elimination of Iodine Deficiency Disorders (IDD) in Central and Eastern Europe, the Commonwealth of Independent States, and the Baltic States. Geneva: WHO; 1998. p. 67-72.

Eastman CJ, Zimmermann MB. The Iodine Deficiency Disorders. [Updated 2018 Feb 6]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK285556

Authors Contribution:
SP- Concept and design of the study, prepared first draft of manuscript; SJ- Reviewed the literature and manuscript preparation; JP- Concept, coordination, statistical analysis; RK- Manuscript editing, revision of the manuscript

Work attributed to:
Madras Medical College and Government Rajiv Gandhi General Hospital, Chennai - 600 003, Tamil Nadu, India

Orcid ID:
Dr. Suresh Pichandi - 𝓓 https://orcid.org/0000-0002-9254-5774
Dr. Sivakumar J - 𝓓 https://orcid.org/0000-0002-6944-7439
Janakiraman P - 𝓓 https://orcid.org/0000-0002-5802-8861
Dr. Ramadevi K - 𝓓 https://orcid.org/0000-0003-0602-5420

Source of Support: Nil, Conflict of Interest: None declared.